A Medivation executive at the heart of the company's team that sold the company to Pfizer for $14 billion five years ago is facing allegations of insider trading.
The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GS